Comparison of the VASP assay and platelet aggregometry in the evaluation of platelet P2Y12 receptor blockade

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 4, 2011, Pages 115-121

  Kuliczkowski, Wiktor ^a   Rychlik, Błazej ^b   Chizyński, Krzysztof ^c   Watała, Cezary ^c   Golański, Jacek ^c  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aggregation; Cangrelor; Clopidogrel; Platelet reactivity; VASP

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ADULT; AGED; ARTICLE; ASSAY; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; INCUBATION TEMPERATURE; INTERMETHOD COMPARISON; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; STENT; THROMBOCYTE AGGREGATION; VASODILATOR STIMULATED PHOSPHOPROTEIN PHOSPHORYLATION ASSAY;

EID: 79955121735     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1037     Document Type: Article

References (19)

1. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007; 167: 1593-1599. (Pubitemid 47280339)
2. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007; 154: 221-231. (Pubitemid 47069129)
3. Gurbel PA, Tantry US. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc Interv. 2010; 3: 1008-1010.
4. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009; 30: 426-435.
5. Bonello L, Tantry US, Marcucci R, et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56: 919-933.
6. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007; 49: 2312-2317. (Pubitemid 46891710)
7. Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther. 2010; 8: 1069-1077.
8. Mueller T, Dieplinger B, Poelz W, et al. Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer - comparison with two flow cytometric methods. Thromb Res. 2007; 121: 249-258. (Pubitemid 350148206)
9. Aleil B, Meyer N, Cazenave JP, et al. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost. 2005; 94: 886-887. (Pubitemid 41489256)
10. Schwarz U R, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999; 82: 1145-1152. (Pubitemid 29419734)
11. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007; 50: 1541-1547. (Pubitemid 47532327)
12. Siller-Matula JM, Gouya G, Wolzt M, et al. Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost. 2009; 102: 397-403.
13. Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost. 2010; 8: 482-488.
14. Siller-Matula JM, Christ G, Lang IM, et al. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost. 2010; 8: 351-359.
15. Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007; 28: 1702-1708. (Pubitemid 47227104)
16. von Beckerath N, Sibbing D, Jawansky S, et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry. Blood Coagul Fibrinolysis. 2010; 21: 46-52.
17. Chow CK, Moayyedi P, Devereaux PJ. Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn. 2009; 119: 564-568.
18. Bates ER. Updated European guidelines on the management of acute myocardial infarction in patients presenting with ST-segment elevation. Pol Arch Med Wewn. 2009; 119: 4-5.
19. King SB, III. 2009 update of the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and guidelines on percutaneous coronary intervention: what should we change in clinical practice? Pol Arch Med Wewn. 2010; 120: 6-8.